FDA approves oral formulation of treatment for amyotrophic lateral sclerosis

FDA

12 May 2022 - Today, FDA approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis. 

Radicava ORS is an orally administered version of Radicava, which was originally approved in 2017 as an intravenous infusion to treat amyotrophic lateral sclerosis, commonly referred to as Lou Gehrig’s disease.

Read FDA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Australia , Dossier